Guangzhou-based biotechnology company Magpie Pharmaceuticals announced on Monday that it has raised a nearly RMB100 million (US$14.8 million) series B financing round from Chinese venture capital firm Sangel Capital.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.
Register Basic AccountSubscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!
More Info
Already have an account or paid subscription? Log in
